Sclerotherapy plus octreotide versus sclerotherapy alone in the prevention of early rebleeding from esophageal varices: A randomized, double‐blind, placebo‐controlled, multicenter trial
Massimo Pkimignani, Bruno Andreoni, Luca Carpinelli, Alfonso Capria, Gabriele Rocchi, Ivano Lorenzini, Carlo Staudacher, Luigi Beretta, Roberta Motta, Roberto DeFranchis – 1 May 1995 – Because of its ability to decrease portal pressure, azygos blood flow, and postprandial splanchnic hyperemia, octreotide administration could be effective in reducing early rebleeding in patients undergoing endoscopic variceal sclerotherapy (EVS). We report the results of a trial comparing EVS + octreotide versus EVS alone.